3 Possible Catalysts for Inovio Pharmaceuticals in 2014

Inovio Pharmaceuticals could be a stock to watch in 2014 for these three reasons.

Feb 12, 2014 at 4:59PM

There's a real buzz around Inovio Pharmaceuticals (NASDAQ:INO).

Indeed, shares have have risen from $0.72 one year ago to $2.82 at the time of writing. That's a gain of 291%. I don't need to tell you that the major U.S. indices posted gains that were only fractions of that amount over the same period.

Moreover, much of that gain has come the last eight months or so, and the buzz surrounding Inovio Pharmaceuticals culminated in the company being invited by the New York Stock Exchange to ring the opening bell on Feb. 12.

Much of the hype surrounding Inovio has to do with the future -- more specifically, the potential catalysts for the stock. Here are three that could be worth keeping an eye on throughout 2014 (this list is not exhaustive).

1. The exclusive worldwide partnership with Roche to develop and commercialize products from Inovio Pharmaceuticals' prostate cancer and hepatitis B immunotherapy programs appears to be making encouraging progress. Although Inovio remains tight-lipped about the identity of other large pharmaceutical companies with whom it is in discussions, those discussions are ongoing and further news is likely to surface during the year.

2. Although Inovio manages a relatively broad portfolio of immunotherapies, its lead program remains focused on cancer immunotherapy. Efficacy data from the phase 2 trial of this program is due to be released in the second or third quarter of this year and could have a major impact on the stock price.

3. Inovio expects to update the market throughout the year on both its prostate cancer and hepatitis B therapies with Roche, but also initiate several new clinical trials for cancer immunotherapies. Updates from these trials could impact the stock price, too.

Of course, Inovio Pharmaceuticals isn't the only stock garnering some buzz in 2014. Other health care companies that are focused on immunotherapies have also seen their share prices deliver notable movements, with two obvious examples being ImmunoCellular Therapeutics (NYSE MKT:IMUC) and Galena Biopharma (NASDAQ:GALE).

ImmunoCellular Therapeutics has seen its share price move from roughly $0.92 at the start of the year to $1.21 as of the closing bell Wednesday, although it should be noted that it reached as high as $1.56 before pulling back. As with Inovio, the company has numerous potential catalysts for the year ahead, including a meeting with the FDA to discuss phase 2 results for its lead product candidate, the brain cancer treatment ICT-107, as well as a decision from the European Medicines Agency on whether ICT-107 will be granted an orphan designation.

Meanwhile, Galena Biopharma's share price is at the same level as it was on New Year's Eve. However, this doesn't tell the whole story because the stock has been as much as 50% higher as a result of the company's deal to purchase Mills Pharmaceuticals for $200 million, a strategic partnership for breast cancer drug NeuVax in India, and positive updates surrounding a phase 2 trial for cancer immunotherapy GALE-301.

It could be worth keeping an eye on all three immunotherapy-focused companies. With the buzz surrounding its current share price and the three catalysts mentioned above, 2014 could be a very interesting year for Inovio Pharmaceuticals in particular.

The Motley Fool's Top Stock For 2014

There's a huge difference between a good stock and a stock that can make you rich. The Motley Fool's chief investment officer has selected his No. 1 stock for 2014, and it's one of those stocks that could make you rich. You can find out which stock it is in the special free report "The Motley Fool's Top Stock for 2014." Just click here to access the report and find out the name of this under-the-radar company.

Peter Stephens has no position in any stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

4 in 5 Americans Are Ignoring Buffett's Warning

Don't be one of them.

Jun 12, 2015 at 5:01PM

Admitting fear is difficult.

So you can imagine how shocked I was to find out Warren Buffett recently told a select number of investors about the cutting-edge technology that's keeping him awake at night.

This past May, The Motley Fool sent 8 of its best stock analysts to Omaha, Nebraska to attend the Berkshire Hathaway annual shareholder meeting. CEO Warren Buffett and Vice Chairman Charlie Munger fielded questions for nearly 6 hours.
The catch was: Attendees weren't allowed to record any of it. No audio. No video. 

Our team of analysts wrote down every single word Buffett and Munger uttered. Over 16,000 words. But only two words stood out to me as I read the detailed transcript of the event: "Real threat."

That's how Buffett responded when asked about this emerging market that is already expected to be worth more than $2 trillion in the U.S. alone. Google has already put some of its best engineers behind the technology powering this trend. 

The amazing thing is, while Buffett may be nervous, the rest of us can invest in this new industry BEFORE the old money realizes what hit them.

KPMG advises we're "on the cusp of revolutionary change" coming much "sooner than you think."

Even one legendary MIT professor had to recant his position that the technology was "beyond the capability of computer science." (He recently confessed to The Wall Street Journal that he's now a believer and amazed "how quickly this technology caught on.")

Yet according to one J.D. Power and Associates survey, only 1 in 5 Americans are even interested in this technology, much less ready to invest in it. Needless to say, you haven't missed your window of opportunity. 

Think about how many amazing technologies you've watched soar to new heights while you kick yourself thinking, "I knew about that technology before everyone was talking about it, but I just sat on my hands." 

Don't let that happen again. This time, it should be your family telling you, "I can't believe you knew about and invested in that technology so early on."

That's why I hope you take just a few minutes to access the exclusive research our team of analysts has put together on this industry and the one stock positioned to capitalize on this major shift.

Click here to learn about this incredible technology before Buffett stops being scared and starts buying!

David Hanson owns shares of Berkshire Hathaway and American Express. The Motley Fool recommends and owns shares of Berkshire Hathaway, Google, and Coca-Cola.We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

©1995-2014 The Motley Fool. All rights reserved. | Privacy/Legal Information